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Chronic kidney disease (CKD) is a known complication of the
human immunodeficiency virus (HIV) but outcomes among
HIV-infected patients with kidney disease are unknown.
We studied a national sample of 202 927 patients with CKD
(stage 3 or higher) for death, end-stage renal disease (ESRD)
and the mean annual rate of decline in estimated glomerular
filtration rate (eGFR) over a median period of 3.8 years.
Within this sample, 0.3% of the patients were diagnosed with
HIV, 43.5% were diabetic, whereas the remainder had neither
disease. In this national CKD cohort, HIV-infected black
patients were at higher risk of death, a similar risk for ESRD
and loss of eGFR than black patients with diabetes.
HIV-infected white patients experienced higher rates of death
but a lower risk of ESRD than their counterparts with
diabetes. Our results highlight a need to study mortality and
mechanisms of ESRD in the HIV infected population.
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Although highly active antiretroviral therapy has resulted in
dramatic improvements in morbidity related to the human
immunodeficiency virus (HIV), many contemporary studies
indicate that kidney disease is an increasingly frequent
complication of HIV infection.1,2 In the United States, the
prevalence of end-stage renal disease (ESRD) caused by HIV-
associated nephropathy doubled between 1995 and 2000 and
proteinuria may be present in up to 30% of HIV-infected
individuals.1,3,4 Kidney disease is also an important predictor
of mortality among patients with HIV. Between 1995 and
1999, the proportion of death certificates listing kidney
disease as an underlying cause increased from 6 to 9% among
HIV-infected individuals nationally.5
Prior work has demonstrated that elevated serum
creatinine and proteinuria together or independently predict
mortality among patients with HIV.3,5–11 However, relatively
few studies have examined clinical outcomes among
representative samples of patients with HIV and chronic
kidney disease (CKD). Previous studies of outcomes in HIV-
infected patients with renal disease were conducted among
cohorts undergoing kidney biopsy 3,6–9 and women,10,11 and
thus may not be generalizable to the wider population of
patients with HIV and CKD. To date, no studies have
examined the incidence of ESRD, death, and loss of kidney
function in large population of HIV-infected individuals with
established CKD. The objective of this study was to
characterize rates of death, ESRD, and kidney function
decline among HIV-infected individuals in a national
contemporary cohort of patients with CKD and compare
them to rates among individuals with diabetes.
RESULTS
Among the 202 927 patients included in this study, 534
(0.3%) had HIV, 88 340 (43.5%) had diabetes, and 114 223
(56.3%) did not have either condition (Table 1). Patients
with HIV were younger (55.9 years710.1) than patients with
diabetes (73.1 years78.8) or patients without HIV or
diabetes (73.6 years79.0). Among patients with HIV,
50.4% (n¼ 269) were black, whereas only 13.1%
(n¼ 11 575) of those with diabetes and 9.2% (n¼ 10 531)
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of patients without either condition were black. The
prevalence of severe CKD (estimated glomerular filtration
rate (eGFR) 15–29 ml/min/1.73 m2) and renal failure
(eGFRo15 ml/min/1.73 m2) was higher among patients with
HIV (18.0%) compared with patients with diabetes (13.1%)
and those without either condition (8.0%). Cardiovascular
diseases were common in all groups, but were most prevalent
in patients with diabetes. Hepatitis C virus coinfection was
found in 27.3% (n¼ 146) of HIV-infected patients, whereas
only 1.3% (n¼ 1182) of patients with diabetes and 1.0%
(n¼ 1144) of patients without either condition had hepatitis
C virus. A higher percentage of patients with HIV (43.6%,
n¼ 233) were in the lowest tertile of socioeconomic status
compared with patients with diabetes (35.7%, n¼ 31 474) or
patients without HIV or diabetes (33.6%, n¼ 38 339).
Among HIV-infected individuals, rates of treatment with
highly active antiretroviral therapy at the time of cohort entry
were comparable between white (20.4%) and black (17.5%)
patients (P¼ 0.461). Mean CD4þ T-cell counts and HIV
RNA levels were also similar between white and black
patients at baseline (328 versus 305 cells/mm3, P¼ 0.412, and
2.86 versus 3.15 log copies/ml, P¼ 0.297, respectively).
The median observation time was 3.8 (interquartile range
3.2–4.0) years. A total of 8922 cases of ESRD and 46 032
deaths occurred during 664 446 person-years of observation.
Among HIV-infected patients, there were 121 deaths and 102
cases of ESRD over 1536 person-years of observation
(Table 2). The majority of these cases (66 deaths and 85
cases of ESRD) occurred among black patients. Among
patients with diabetes, there were 5991 cases of ESRD and
22 094 deaths during 272 847 person-years of follow-up.
Death
Mortality rates were much higher among patients with HIV
compared with all other groups (Table 2). Among black
patients, the age- and sex-adjusted mortality rate (per 1000
person-years) among HIV-infected individuals, 120.5 (con-
fidence interval (CI) 90.9–150.1), was approximately double
the rate found among those with diabetes, 60.4 (CI
57.4–63.4). Among white patients, the age- and sex-adjusted
Table 1 | Demographic and clinical characteristics of the cohort at baseline
Variable Total cohort n (percent) HIV n (percent) Diabetes n (percent) No HIV or diabetes n (percent) P-value*
202 927 (100.0) 534 (0.3) 88 340 (43.5) 114 223 (56.3) o0.001
Age (years)a 73.178.8 55.9710.1 72.578.5 73.679.0 o0.001
Race o0.001
White 180 638 (89.0) 265 (49.6) 76 765 (86.9) 103 692 (90.8)
Black 22 289 (11.0) 269 (50.4) 11 575 (13.1) 10 531 (9.2)
Sex o0.001
Male 196 600 (96.9) 529 (99.1) 86 195 (97.6) 110 045 (96.3)
Female 6327 (3.1) 5 (0.9) 2145 (2.4) 4178 (3.7)
CKD (eGFR) o0.001
45–59 120 587 (59.4) 298 (55.8) 48 152 (54.5) 72 226 (63.3)
30–44 61 594 (30.4) 140 (26.2) 28 597 (32.4) 32 903 (28.8)
15–29 17 838 (8.8) 67 (12.6) 9908 (11.2) 7889 (6.9)
o15 2908 (1.4) 29 (5.4) 1683 (1.9) 1205 (1.1)
Serum creatinine (mg/dl) 1.7570.76 2.3171.63 1.8370.82 1.6970.69 o0.001
Comorbidities
HIV 534 (0.3) — 170 (0.2) —
DM 88 340 (43.5) 170 (31.8) — —
HTN 183 959 (90.7) 367 (68.7) 83 586 (94.6) 100 156 (87.7) o0.001
CAD 123 657 (60.9) 136 (25.5) 59 778 (67.8) 63 809 (55.9) o0.001
CHF 70 733 (34.9) 93 (17.4) 37 884 (42.9) 32 802 (28.7) o0.001
CVA 57 199 (28.2) 62 (11.6) 28 263 (32.0) 28 907 (25.3) o0.001
PVD 61 370 (30.2) 67 (12.6) 32 358 (36.6) 28 976 (25.4) o0.001
COPD 79 317 (39.1) 153 (28.7) 34 650 (39.2) 44 574 (39.0) o0.001
HCV 2423 (1.2) 146 (27.3) 1182 (1.3) 1144 (1.0) o0.001
SES Level o0.001
Lowest 69 960 (34.5) 233 (43.6) 31 474 (35.7) 38 339 (33.6)
Middle 68 409 (33.7) 145 (27.2) 29 243 (33.1) 39 073 (34.2)
Highest 64 427 (31.8) 156 (29.2) 27 563 (31.2) 36 740 (32.2)
CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; DM, diabetes mellitus; eGFR,
estimated glomerular filtration rate in ml/min/1.73 m2; HCV, hepatitis C virus infection; HIV, human immunodeficiency virus; HTN, hypertension; PVD, peripheral vascular
disease; SES, socioeconomic status.
*P-value for differences between HIV, diabetic, and non-HIV/non-DM groups.
aAge expressed as the mean with s.d.
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incidence of death per 1000 person-years was 70.8 (CI
52.0–90.0) among HIV-infected patients, 50.3 (CI 49.3–51.3)
for patients with diabetes, and 35.0 (CI 34.2–35.7) for
patients with neither condition. After multivariate adjust-
ment, a two-fold increased hazard ratio (HR) for death was
also observed for HIV in both white 2.21 (CI 1.57–3.13) and
black 2.32 (CI 1.70–3.18) racial groups when compared with
the referent group with no HIV or diabetes, respectively. In
the subgroup of individuals with ageo65 years, the adjusted
risk of death did not change substantially for all groups.
Among black individuals, the adjusted HR for death was 2.47
(HR 1.72–3.55) for HIV and 1.14 (HR 0.97–1.33) for diabetes.
ESRD
The age- and sex-adjusted incidence rates of ESRD per 1000
person-years were similar between black patients with
HIV and diabetes, 71.1 (95% CI 55.4–86.7) versus 59.9
(CI 56.7–63.1), as shown in Table 2. Rates in these groups
were higher than those among black patients with neither
condition (27.9, CI 25.7–30.1). In contrast, among white
patients, the age- and sex-adjusted incidence of ESRD
per 1000 person-years was much lower in patients with
HIV, 11.3 (CI 5.9–16.6), than patients with diabetes, 22.0
(CI 21.2–22.8), and similar to the rate among patients
with neither condition, 7.8 (CI 7.5–8.3). In multivariate
Cox proportional hazard analysis, both HIV (HR 2.11,
CI 1.46–3.06) and diabetes (HR 1.78, CI 1.63–1.93) were
strongly associated with ESRD among black patients when
compared with the referent group with neither condition.
Among white patients, diabetes doubled the risk of ESRD
(HR 1.97, CI 1.86–2.08), but HIV was not associated with an
increased risk of ESRD (HR 0.68, CI 0.26–1.76). Among
cohort members with age o65 years, the adjusted HR for
ESRD was 2.08 (CI 1.44–3.00) for black patients with HIV
and 1.88 (CI 1.67–2.12) for black patients with diabetes.
Mean annual change in eGFR
Point estimates for rates of eGFR decline were greatest among
black patients with HIV compared with other groups
throughout the range of baseline eGFR (Table 3); however,
Table 2 | Incidence rates and adjusted risk of ESRD and deatha
Persons (n)
Time at risk
(person-years)
ESRD
events (n)
Deaths
(n)
Age and Sex
adjusted rates of
ESRD (per 1000
person-years)
Multivariate
hazard ratio
for ESRDb
Age and sex
adjusted rates of
death (per 1000
person-years)
Multivariate
hazard ratio
for deathb
White
No HIV or
diabetes
103 692 338 985 2065 20 366 7.8 (7.5–8.3) Referent 35.0 (34.2–35.7) Referent
HIV 265 863 17 55 11.3 (5.9–16.6) 0.68 (0.26–1.76) 70.8 (52.0–90.0) 2.21 (1.57–3.13)
Diabetes 76 765 239 224 4183 19 313 22.0 (21.2–22.8) 1.97 (1.86–2.08) 50.3 (49.3–51.3) 1.23 (1.21–1.26)
Black
No HIV or
diabetes
10 531 32 434 808 2354 27.9 (25.7–30.1) Referent 49.7 (46.8–52.6) Referent
HIV 269 674 85 66 71.1 (55.4–86.7) 2.11 (1.46–3.06) 120.5 (90.9–150.1) 2.32 (1.70–3.18)
Diabetes 11 575 33 623 1808 2781 59.9 (56.7–63.1) 1.78 (1.63–1.93) 60.4 (57.4–63.4) 1.06 (1.00–1.12)
ESRD, end stage renal disease; HIV, human immunodeficiency virus.
Numbers in parentheses indicate 95% confidence intervals.
aThere were 170 patients who had both HIV and diabetes and contributed to event rates for both groups. The multivariate hazard ratio for ESRD and death utilize interaction
terms to exclude the effect of overlap between diagnoses and isolate the individual effect of HIV and diabetes, respectively.
bAdjusted for age, race, sex, baseline estimated glomerular filtration rate, hypertension, coronary artery disease, heart failure, chronic obstructive lung disease, peripheral
vascular disease, hepatitis C infection, cerebrovascular disease, and socioeconomic status.
Table 3 | Age and sex-adjusted rates of mean eGFR change per year stratified by race, HIV or diabetes status, and starting eGFR
category
Overall
eGFR 45-59 ml/min/1.73 m2
at baseline
eGFR 30-44 ml/min/1.73 m2
at baseline
eGFR 15-29 ml/min/1.73 m2
at baseline
White race
No HIV or diabetes 0.1 (0.1, 0.1) 0.1 (0.2, 0.1) 0.1 (0.1, 0.0) 0.8 (0.9, 0.7)
HIV 0.4 (1.3, 0.5) 0.1 (0.9, 0.8) 0.6 (2.0, 0.7) 3.8 (7.1, 0.5)
Diabetes 1.4 (1.4, 1.3) 1.4 (1.4, 1.3) 1.5 (1.6, 1.4) 1.8 (1.9, 1.7)
Black race
No HIV or diabetes 0.8 (0.9, 0.7) 0.4 (0.5, 0.3) 1.2 (1.4, 1.0) 2.0 (2.4, 1.7)
HIV 3.7 (5.2, 2.1) 2.9 (4.5, 1.3) 3.5 (5.5, 1.6) 4.0 (6.8, 1.2)
Diabetes 2.3 (2.4, 2.1) 2.0 (2.1, 1.8) 2.5 (2.7, 2.3) 3.2 (3.4, 2.9)
eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus.
Rates are reported in ml/min/1.73 m2 per year with 95% confidence intervals reported in parentheses.
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these differences were not statistically significant when
compared with rates among black patients with diabetes.
The mean annual change in eGFR among white individuals
with HIV was low, except among patients with severe CKD at
baseline (eGFR of 15–29 ml/min/1.73 m2). Among black
patients o65 years, overall rates of eGFR change per year
were 4.8 (CI 7.4, 2.2) for HIV-infected patients and
2.4 (CI 2.8, 1.9) for patients with diabetes.
DISCUSSION
In this large, national sample of veterans with CKD, we found
that the impact of HIV on rates of death, ESRD, and kidney
function decline differed significantly by white/black race.
HIV was a strong risk factor for mortality in both white and
black patients with CKD, however, black individuals with
HIV had higher rates of death, ESRD and renal function
decline when compared with their white counterparts.
Furthermore, black individuals with HIV had higher rates
of death, and similar rates of ESRD and renal function
decline compared with the high-risk group of black patients
with diabetes. In contrast, among HIV-infected white
individuals with CKD, we observed relatively high mortality
rates, but a low incidence of ESRD, and modest rates of eGFR
decline. Our results highlight the need to investigate
mechanisms for ESRD and death in the HIV-infected
population and reasons for racial differences in outcomes.
Prior studies have supported the association between CKD
and mortality among HIV-infected individuals. In the HIV
Epidemiology Research Study (HERS), among 885 HIV-
infected women, renal abnormalities at baseline (defined as
proteinuria or an increased creatinine 41.4 mg/dl) were
associated with an adjusted HR of 2.5 (1.9–3.3) for
mortality.11 Extending these results, an analysis from the
Women’s Interagency HIV Study (WIHS) found that the
presence of proteinuria and elevated serum creatinine level
was independently associated with an increased risk of death
among HIV-infected women.10 These studies examined a
total of approximately 350 women with kidney disease at
baseline and did not analyze progression to ESRD, rates of
kidney function decline, or provide comparisons with HIV-
negative groups. Case series of HIV-infected individuals with
CKD have also established high-mortality rates in this patient
group. However, these studies were limited to patients who
were evaluated by kidney biopsy, and were conducted before
the advent of antiretroviral therapy.3,6–9
Our study builds on these findings by examining the
impact of HIV in the context of a large, predominantly
male, contemporary patient population with CKD. Three
significant clinical outcomes, including death, ESRD, and
rates of eGFR decline were analyzed, providing a broad,
inclusive view of the clinical implications of CKD among
HIV-infected individuals. In addition, the use of HIV-
negative controls in this study allows comparison with
established risk factors for ESRD such as diabetes, and
illustrates areas where the care for HIV-infected patients with
CKD could be improved. Finally, the large number of
patients with CKD allows a detailed characterization of the
interaction between CKD and race.
Prior studies have recognized that CKD is an independent
risk factor for mortality in the general population.12,13 In our
study, even within the context of this high risk group, both
white and black patients with HIV had increased mortality
when compared with other disease states, such as diabetes. It
is unclear why mortality in the setting of CKD should be
magnified by HIV infection. In general, increased mortality
among CKD patients has been attributed to cardiovascular
disease,12,14 prompting recommendations for cardiovascular
risk reduction as part of CKD management.15 In this cohort,
the relatively low prevalence of cardiovascular disease among
patients with HIV suggests that alternative mechanisms of
mortality may be relevant to the HIV-infected CKD
population. Although, some studies have found that
cardiovascular disease is increased in the setting of HIV-
infection compared with HIV-negative controls,16,17 morta-
lity rates in HIV-infected individuals included in kidney
biopsy studies appear to correlate with the severity of HIV
infection.9,18,19 Among HIV-infected women in the HERS
cohort, HIV or AIDS-related causes were recorded on death
certificates of 58% of patients with elevated creatinine or
proteinuria. Data from the WIHS cohort suggest that
elevated serum creatinine levels are a predictor for the
development of the acquired immune deficiency syndrome
(AIDS).10 Collectively, these observations raise the question
of whether the optimal approach to reducing mortality in
HIV-infected individuals with CKD differs from the strategy
used in the HIV-negative population. Further studies are
needed to elucidate mechanisms for increased death in this
group in the present era of antiretroviral therapy and to
determine whether interventions focused on virologic
suppression can improve CKD outcomes.
Although both black and white HIV-infected patients in
this cohort had higher death rates than their counterparts
with diabetes, black patients also had much higher rates of
progression to ESRD and experienced a faster mean decline
in eGFR than white patients with HIV. Rates of ESRD among
black patients with HIV were similar to those in the high-risk
group of black patients with diabetes. These findings are
consistent with the known overrepresentation of black
patients in the United States Renal Data System dialysis
registry1,20,21 and in renal biopsy series conducted in HIV-
infected patients.6,9,19,22,23 In addition, black race is known to
be a risk factor for the development of CKD among HIV-
infected persons.3,24 Although the racial predilection of
kidney disease among HIV-infected individuals has been
established, the magnitude of these differences in comparison
with other high risk groups, such as those with diabetes, had
previously not been well characterized. Collectively, these
findings raise the question of whether the optimal approach
to CKD management among HIV-infected individuals may
differ according to the race of the patient. Among black
individuals, early identification of CKD and interventions to
slow progression of renal disease are of paramount
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importance. Among white patients, particularly those with
only moderate reductions in eGFR, interventions focused on
mortality reduction may have a greater benefit than those
directed at slowing progression of renal disease. Perhaps most
importantly, these striking racial differences in CKD
progression among patients with HIV highlight the critical
need for studies devoted to the understanding of underlying
disease mechanisms for HIV-related renal disease.
The strengths of our study include its large sample size,
national scope, and the availability of high-quality outcome
data on death and ESRD. Our study also has several
limitations, which are primarily related to the use of ‘real
world’ clinical data obtained as part of routine clinical care
and obtained in a single health care system. Specifically, the
cohort was limited to patients who met criteria for CKD
based on having two eGFR measurements at least 3 months
apart. Our sample thus excluded patients who may have had
CKD but did not undergo the requisite number and spacing
of creatinine measurements required for cohort entry.
Although this limitation is unlikely to impact our primary
finding of race differences in outcomes among patients with
HIV and CKD, it may have resulted in inflated rates of ESRD
among cohort members.
Use of the Modification of Diet in Renal Disease (MDRD)
equation to estimate GFR has several limitations. This
equation may be inaccurate in the clinical setting, where
creatinine measurements are not typically calibrated the
MDRD laboratory at the Cleveland Clinic.25 In addition, the
MDRD equation has not been independently validated as a
measure of GFR among HIV-infected persons. It is possible
that systematic differences in the accuracy of the MDRD
equations among patients with and without HIV may
contribute to the observed differences in outcomes. Never-
theless, the prognostic significance of eGFR among patients
with HIV reported here is highly relevant to clinical practice.
Estimation of GFR using the MDRD equation has been
widely incorporated into routine clinical care and this
method is specifically recommended by current Infectious
Disease Society of America Guidelines for assessment of
kidney function in the HIV-infected population.4,15
Our study included a national sample of predominantly
male patients who were insured and received care in the
Department of Veterans Affairs (VA) health-care system.
Results may not be generalizable to uninsured patients, non-
veteran populations, women, or other race/ethnic groups not
studied here. Previous studies have shown that veterans
receiving care at the VA have a higher prevalence of
comorbidity when compared with non-veterans in both
diabetic and non-diabetic populations.26,27 However, HIV-
infected veterans receiving care in the VA appear to have less
AIDS-defining conditions and higher CD4þ counts than
non-veterans.28 Therefore, relative differences in CKD out-
comes between HIV-infected and diabetic populations may
be conservative estimates when compared with settings
outside of the VA health-care system. It should also be noted
that although the gender composition of the veteran
population studied here is mostly male, approximately 80%
of HIV-infected persons in the United States are also male.29
Overall rates of change in eGFR per year in this cohort
were relatively low.30–33 Low rates of eGFR decline may be in
part reflect our study design: we excluded creatinine
measurements within 90 days of death or ESRD and patients
with an eGFR o15 ml/min/1.73 m2 at baseline; we included
only patients receiving outpatient care and had undergone at
least two creatinine measurements at least 3 months apart
(i.e. those who were likely to have their kidney disease
actively managed by a physician). It is also possible that low
observed rates of eGFR decline may reflect the advanced age
of the group studied. Repeated measures analysis may also be
prone to regression to the mean, which may cause rates to
appear lower than expected.34,35
Despite adjusting our analyses for a large number of
comorbid conditions and sociodemographic characteristics,
the possibility of residual confounding by factors not
included in the analysis (e.g. proteinuria, body mass index,
diet) or by differences in disease severity (e.g. stage of heart
failure or severity of diabetes) that could not be defined by
the data sources available to us cannot be ruled out. We also
relied on ICD-9 codes to identify patients with diabetes,
which may have lead to some patients being misclassified.
However, it is reassuring that incidence rates for ESRD and
mortality are of similar magnitude with previously published
estimates.36–38
CONCLUSION
HIV-infection has important clinical implications among
patients with CKD. Although HIV is a strong risk factor for
mortality in both white and black CKD patients, rates of
death, ESRD, and renal function decline differ greatly
between HIV-infected patients of white or black race. These
differences raise the question of whether race should be a
consideration in the management of patients with HIV and
CKD and highlight the importance of future investigations
into causes of death and mechanisms underlying progression
of kidney disease in this population.
MATERIALS AND METHODS
Patients
Our goal was to identify a cohort of patients who fulfilled the
National Kidney Foundation definition for CKD stage 3 or higher.15
A total of 2 352 584 veterans age 18–100 years had at least one
outpatient serum creatinine measured at a Department of VA facility
between October 1, 2000 and September 30, 2001. Among these
patients, 11 125 who had already reached ESRD (defined as receipt
of chronic dialysis or kidney transplant) were excluded. Next, eGFR
was calculated using the abbreviated MDRD formula based on age,
sex, race, and serum creatinine. There were 1 897 758 patients with
an eGFR X60 ml/min/1.73 m2 who were eliminated.39,40 From the
remaining group (n¼ 445 108), there were 209 622 patients who had
an eGFRo60 ml/min/1.73 m2 for at least 3 months prior based on a
second outpatient serum creatinine measurement. Each patient’s
date of first creatinine measurement between October 1, 2000 and
September 30, 2001 was used as the point of cohort entry. There
1384 Kidney International (2007) 72, 1380–1387
o r i g i n a l a r t i c l e AI Choi et al.: Chronic kidney disease outcomes in HIV infection
were 4701 (2.2%) patients in whom race was unknown and 1994
(1.0%) patients who were neither white nor black. These patients
were excluded, leaving an analytic cohort of 202 927 patients.
Data sources
The data sources used to assemble the study cohort have been
described in detail previously.41 The VA Decision Support System
Laboratory Results file provided serum creatinine measurements
associated with outpatient visits.42 The Immunology Case Registry
(ICR) was used to identify all patients with HIV.43 The ICR is a
national VA administrative database designed to monitor health-
care utilization among all of its HIV-infected patients. The ICR, VA
National Patient Care Database, Fee Basis files, and inpatient and
outpatient Medicare claims were used to ascertain demographic and
comorbidity information.44,45 When available, race information
from the Medicare denominator file was used preferentially based on
its superior reliability to VA race data.46 Since 2003, the VA adopted
a new system of race reporting to conform with federal guidelines
and in doing so, established 95% agreement between observer
reported data with self-reported race.47 Overall, 95.6% (n¼ 193 966)
of patients in our cohort had race characterized by Medicare or
updated VA data sources. Patients treated with chronic dialysis or
kidney transplant were identified using the United States Renal Data
System, a comprehensive national ESRD registry.48 Date of death
information for cohort members was provided by the VA
Beneficiary Identification and Records Locator Subsystem.49–51
Area-level socioeconomic data were obtained by matching an
individual’s residential zip code to year 2000 United States Census
zip code tabulation areas.52
Outcomes
The outcomes for our study included time from cohort entry to: (1)
onset of ESRD (defined as initiation of chronic dialysis or kidney
transplantation) or (2) death through September 30, 2004. Patients
were censored at the time of the first occurrence of death, ESRD, or
September 30, 2004. In a supplementary analysis, mean annual rates
of eGFR change were calculated based on serial serum creatinine
measurements available during follow-up.
Primary predictors
The primary predictor for our analysis was the presence of HIV
infection. Patients with HIV were identified by matching our cohort
to the ICR. We considered only patients that entered the ICR before
the time of cohort entry. A diagnosis of HIV was confirmed before
the time of cohort entry based on previous treatment with
antiretroviral therapy or the Centers for Disease Control and
Prevention (CDC) case definition.53 Diabetes status was designated
using methods validated for VA administrative databases based on
information entered between January 1, 1999 and the time of cohort
entry.54 Patients without HIV or diabetes served as the referent
group for evaluating the relative hazard of ESRD and death.
Covariates
In multivariate models, analyses were adjusted for age, sex, and the
following diagnosed conditions based on International Classification
of Diseases, ninth Revision (ICD-9) and Current Procedural
Terminology codes: coronary artery disease (defined as a prior
diagnosis of coronary artery disease, angina, or myocardial
infarction or prior coronary artery bypass graft or angioplasty),
congestive heart failure, hypertension, peripheral arterial disease
(defined as a prior diagnosis of peripheral arterial disease or prior
lower extremity amputation or revascularization procedure),
chronic obstructive pulmonary disease, cerebrovascular disease
(defined as prior stroke or transient ischemic attack), and hepatitis
C virus infection status.41 All analyses were stratified by white/black
race to accommodate a race interaction. We also adjusted for eGFR
at the time of cohort entry. Socioeconomic status was classified
using area-level socioeconomic factors derived from US Census
data: median household income, median value of housing units,
percentage of residents older than 25 years who are high school
graduates, percentage of residents older than 25 years with a
bachelor’s degree, number of residents in executive, managerial, or
professional specialty occupations, number of families below the
poverty level, and number of housing units occupied by the owner.
Using a technique reported previously for census blocks, we
calculated a z-score for each zipcode by subtracting the mean value
for the variable and dividing by the standard deviation.55 Overall
summary scores for socioeconomic status were derived for each
patient by summing z-scores for each socioeconomic variable.
Patients were then divided into tertiles according to summary
socioeconomic scores. Socioeconomic information was not available
due to missing zip code information in o0.1% of patients (n¼ 9)
and because zip codes could not be linked to a zip code tabulation
area in the US census in 2.4% of patients (n¼ 4.938). For patients
with missing information on zip code socioeconomic status, a
missing indicator variable for socioeconomic status was included in
multivariate analysis.
Statistical analyses
Baseline characteristics were compared among cohort patients with
HIV, diabetes, and patients without either of these conditions using
the w2 test for categorical variables and the ANOVA test for
comparison of means for continuous variables. Age- and sex-
adjusted incidence rates for ESRD and death were obtained using a
parametric regression survival-time model fitted to the exponential
distribution and standardized to the median age of the source
population. Cox proportional hazard analysis was used to compare
the adjusted association of HIV with time to ESRD and time to
death, respectively, with patients without HIV or diabetes serving as
the referent group. Interaction terms for HIV and diabetes were
utilized to isolate the effect of HIV and diabetes, respectively; that is
this allowed us to exclude the effect of having both conditions
simultaneously. For these analyses, patients were censored at the
time of first occurrence of death, ESRD, or September 30, 2004.
Estimates were adjusted for age, sex, eGFR, baseline comorbidities,
and socioeconomic status.
Rates of change in eGFR (ml/min/1.73 m2 per year) were
estimated using a mixed effects linear regression model, which
accounted for variations in the number and spacing of creatinine
measurements and length of follow-up for each subject. For this
analysis, 2908 patients who had already reached renal failure at the
time of cohort entry (eGFR o15 ml/min/1.73 m2) were excluded.
To avoid analyzing creatinine measurements occurring near the time
of death or onset of ESRD (which may not reflect chronic rates of
progression), we also excluded 66 104 eGFR measurements that
occurred 90 days before ESRD or death. Thus, our analyses were
conducted among 196 418 patients who contributed 1 840 815
creatinine measures to our analysis.
A supplementary analysis of these outcomes was performed
among the subgroup of patients with age o65 years. All regression
models were validated when checked by bootstrap methods and
by comparing robust standard errors. For Cox models, the
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proportional hazards assumption was checked using the Schoenfeld
test and by graphically comparing stratified log (log (survivor
function)) versus time curves. Assumptions of the mixed effects
model were tested and satisfied. Analyses were conducted using
Stata version 9.0 (Stata Corp, College Station, TX, USA). This study
was approved by the Institutional Review Board at the University of
California, San Francisco, and the Research Committee at the VA
San Francisco.
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